Discover how Lifestream Pharma successfully renewed the CE mark for their BioXtra Dry Mouth products under the EU MDR. Learn about the challenges faced, the approach taken for compliance, and the results achieved.
Transitioning from the MDD to MDR presents significant challenges. For Lifestream Pharma, the creator and owner of the bioXtra range of products, achieving MDR compliance was a critical milestone. QbD Group successfully partnered with Lifestream to ensure the smooth renewal of their CE marking under MDR, guaranteeing continued compliance and market presence for these well-established products.
bioXtra products have been a trusted name in oral care for over 24 years, highlighting Lifestream Pharma‘s long-standing reputation for quality and innovation. Lifestream played a pivotal role in developing these products. With a portfolio spanning both cosmetic and medical device industries, Lifestream Pharma stands at the forefront of advancing health and beauty solutions globally.
The transition from MDD to MDR compliance can be daunting, requiring meticulous preparation and in-depth regulatory expertise. Lifestream’s journey was no exception.
Lifestream Pharma partnered with both our Regulatory Affairs and Clinical division.
The collaboration with QbD Group was instrumental in overcoming these challenges, ultimately achieving the CE marking for the bioXtra product line under the new MDR framework.
Our team provided tailored support, focusing on strategic project management, regulatory expertise, and thorough documentation processes to meet MDR requirements.
By addressing complexities with precision and care, QbD ensured that Lifestream could confidently navigate this critical transition.
Through our partnership, Lifestream Pharma successfully maintained compliance and upheld the high standards synonymous with the bioXtra brand.
QbD Group
Ready to accelerate your life sciences project? Talk to our experts.
Get expert guidance →Keep reading
Case StudyThe landscape of medical device regulations is constantly evolving, making it a challenge for companies to keep up. Our collaboration with Oystershell, which began in July 2023, highlights our expertise in transforming complex challenges into success stories, all with a touch of QbD Clinical magic.
Read more
Case StudyQbD Clinical assisted Minze Health, a urology-focused medical devices company, in obtaining CE marking under MDR through clinical evaluation.
Read more
Case StudyQbD Group supported software company Relu with their expertise to comply with changing regulations.
Read more